Patents
Literature
42 results about "Eucaryotic cell" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A eukaryotic cell is a cell that contains membrane-bound compartments in which specific metabolic activities take place. Most important among these compartments is the nucleus, which houses the eukaryotic cell's DNA.
Hemonchus contortus subunit vaccine
The invention discloses a haemonchus contortus subunit vaccine, and belongs to the field of veterinary vaccines. The subunit vaccine comprises an antigen protein MEP3, an antigen protein AP1, an antigen protein AP8, an antigen protein H11-2, an antigen protein H11-4 and an antigen protein AP5 of galactosylated and modified haemonchus contortus, and the antigen protein MEP3, the antigen protein AP1, the antigen protein AP8, the antigen protein H11-2, the antigen protein H11-4 and the antigen protein AP5 of galactosylated and modified haemonchus contortus. The galactosylation modification of the antigen protein is realized by jointly expressing glycosyl transferase HcGALT of haemonchus contortus and one or more of the proteins in eukaryotic cells. The antigen protein modified by galactosylation in the subunit vaccine is closer to the glycosylation modification of natural protein, and can provide effective immune protection after the goat is infected with haemonchus contortus, and the egg laying rate is reduced by 81.43%. The invention lays a foundation for development of haemonchus contortus subunit vaccines, provides an effective technical means for prevention and treatment of the haemonchus contortus subunit vaccines, and has important application value and popularization prospect.
Owner:HUAZHONG AGRI UNIV
Double-structural-domain recombinant human chemical fibronectin as well as preparation and application of double-structural-domain recombinant human chemical fibronectin
The invention discloses a double-structural-domain recombinant human fibronectin, the sequence of which is shown as SEQ ID NO.3, and the double-structural-domain recombinant human fibronectin is formed by fusing a collagen binding structural domain and a cell binding structural domain of human fibronectin. The invention also provides a recombinant expression vector containing the protein coding gene and a host cell. The protein is efficiently expressed through eukaryotic cells and engineering bacteria escherichia coli, and a fermentation and purification process suitable for an industrial scale is established in a matched manner. Functional experiments prove that compared with commercially available fibronectin products with a single structural domain, the double-structural domain recombinant human chemical fibronectin disclosed by the invention can remarkably promote proliferation, migration, adhesion and differentiation activity of human skin fibroblasts, and has wide application potential in the fields of skin repair, skincare and biomedical materials.
Owner:BAYI MEIHENG (BEIJING) TECH CO LTD
A camelid single-domain antibody against crp and its preparation method and application
ActiveCN116239686BImmunoglobulins against animals/humansAntibody ingredientsEucaryotic cellElisa kit
This invention discloses a camel-derived CRP single-domain antibody, its preparation method, and its applications, relating to the biomedical field. The method involves enriching CRP antigen in alpaca leukocytes immunized with the antigen, followed by single-cell screening and sequencing. Through sequencing structural analysis, a recombinant plasmid of the camel-derived CRP antibody is constructed. This plasmid is cloned and transformed into eukaryotic cells to express related antibodies. Monoclonal antibodies with human CRP resistance are screened for expression. The VHH domain of the monoclonal antibody is cloned and expressed, and paired screening yields CRP-VHH monoclonal antibodies with antibody activity. This antibody can be used in ELISA kits, chemiluminescence kits, and latex kits, possessing the same functionality as existing kits. Furthermore, this antibody also has applications in the preparation of antitumor drugs.
Owner:BEIJING 3S CENTURY TECH CORP
Engineered modular recombinase compositions, methods, and systems for site-specific DNA recombination
PCT designated stageWO2025212976A2HydrolasesStable introduction of DNAEucaryotic cellSite-specific recombination
Disclosed are altered recombinases wherein at least one amino acid is different from a parent, wildtype recombinase and the altered recombinase has improved recombination efficiency towards wild-type and / or pseudo att site sequences relative to the parent, wildtype recombinase. Disclosed are altered modular recombinases comprising binding (or interacting) regions from a different recombinase. Disclosed are methods of modifying the genomes of cells using the altered recombinases, including methods of site-specifically integrating a polynucleotide sequence of interest in a genome of a eucaryotic cell.
Owner:SANGAMO THERAPEUTICS INC
Genetic enhancement of exosome production
Levels of expression of antibiotic resistance genes are increased up to six-fold by inserting a proteasome-targeting tag into transgenes expressed in eukaryotic cells. Various selectable marker proteins are combined with different destabilization domains, leading to up to 70% increase in transgene expression. The increase in expression varies highly depending on the engineered construct and the lines cells used. Increase in expression drives exosome loading of cargo proteins in some aspects. By increasing expression and by editing trafficking signals of cargo proteins, proteins that normally locate to the ER can be trafficked to exosomes. This disclosure discloses efficient exosome delivery of a wide variety of engineered proteins, including modified antigen proteins of SARS-CoV-2 and influenza, and other proteins such as a modified alpha galactosidase A, an extracellular domain of vascular endothelial growth factor fused to a constant region of a human immunoglobulin heavy chain, and modified trastuzumab heavy and light chains.
Owner:JOHNS HOPKINS UNIVERSITY
Dabie bandavirus mRNA vaccine and preparation method therefor
PCT designated stage expiredWO2025139352A1SsRNA viruses negative-senseVirus peptidesEucaryotic cellEnzyme digestion
Provided are a Dabie bandavirus mRNA vaccine and a preparation method therefor. Specifically an optimized mRNA molecule is provided, and is cloned into a pGEM-3Zf(+)mRNA vaccine vector; the plasmid is linearized by means of enzyme digestion, and subjected to capping and poly(A) tail addition by means of an in-vitro transcriptase method to prepare an mRNA; the obtained mRNA is transfected into eukaryotic cells, and it is verified by means of an immunoblotting experiment that the mRNA can be expressed in vitro; and the mRNA is encapsulated by a lipid nanoparticle delivery system to obtain the mRNA vaccine, which, after immunizing mice, can induce the generation of a relatively high antibody level in serum. A viral neutralization test further proves that the immune serum can bind to viruses to prevent the viruses from infecting cells.
Owner:NANJING MEDICAL UNIV
Vaccine for preventing salmonella infection and application thereof
ActiveCN120192426APolypeptide with localisation/targeting motifAntibacterial agentsEucaryotic cellRecombinant vaccines
The invention relates to a fusion protein for preventing salmonella infection, an immunogenic composition, a recombinant vaccine, a molecular architecture design, application and the like. According to the invention, three fusion proteins, namely PstS-LpfB, PstS-YidR and LpfB-SinH, which can be smoothly expressed in eukaryotic cells are selected to carry out animal immune experiments, so that the protection effect is verified. The invention finds that fusion protein molecules such as PstS-LpfB and the like can weaken tissue lesions caused by salmonella infection, have good immunogenicity, play a role in effective prevention and immune protection, efficiently prevent salmonella infection and have wide application prospects.
Owner:JIANGXI CHENGSHI BIOTECHNOLOGY CO LTD
Directed evolution of membrane proteins in eukaryotic cells with cell walls
Owner:UNIVERSITY OF ZURICH
A transient transfection method for improving recombinant protein expression in CHO cells
PendingCN122445729AEucaryotic cellDeoxycytidylic Acids
The application discloses a transient transfection method for improving recombinant protein expression of CHO cells, and relates to the technical fields of eukaryotic cell gene transfection and animal cell culture. A cell suspension is obtained by mixing a CHO cell and a serum-free CHO cell basic culture medium; DNA and a transfection reagent are added into the cell suspension to mix a transfection culture, 5-azadeoxycytidine acid solution is added into the transfection culture at 0h-24h to form a transfection system and continue the transfection culture; the transfection system is added with a feeding culture medium at 1d-4d after the transfection culture to carry out suspension culture; the suspension culture is centrifuged at 7d to separate and harvest cell culture supernatant to complete recombinant protein expression. According to the application, 5-azadeoxycytidine acid is added into the transfection culture at a specific concentration, so that the expression of recombinant protein of the CHO cell is significantly improved during the transfection expression.
Owner:SUZHOU YOUYI BIOTECHNOLOGY CO LTD
Antibacterial peptide with multi-phytopathogen antibacterial activity, biological antibacterial agent and application of antibacterial peptide and biological antibacterial agent
The invention discloses an antibacterial peptide with multiple phytopathogen antibacterial activity, a biological antibacterial agent and application of the antibacterial peptide and the biological antibacterial agent, and the amino acid sequence of the antibacterial peptide is FKLIRNLIILRQAWKLIKRRR and is marked as RR-21. Experiments show that the antibacterial peptide disclosed by the invention has a similar alpha-helical structure with a known antibacterial peptide LL-37, and has antibacterial activity on plant pathogenic bacteria represented by pseudomonas syringae and plant pathogenic fungi represented by fusarium pseudograminearum and fusarium oxysporum; compared with the LL-37 polypeptide, the MIC of the RR-21 is 4-8 [mu] g / mL, and the RR-21 has a more significant bacteriostatic effect; meanwhile, under the conventional bacteriostatic concentration (less than or equal to 16 mu g / mL), the RR-21 shows no hemolytic activity; the above fully proves that the antibacterial peptide has high biological safety to eukaryotic cells while exerting multiple antibacterial effects, and can be used as an active component of a biological antibacterial agent, and the biological antibacterial agent has the potential of being developed into an efficient and safe plant disease resistant drug or a plant green pesticide.
Owner:LANZHOU UNIV
Specific bacterial fluorescent dye as well as preparation method and application thereof
The invention belongs to the technical field of chemical synthesis and biology, and particularly relates to a specific bacterial fluorescent dye and a preparation method and application thereof, in particular to a fluorescent dye which can be used for dyeing bacteria but not fungi. Existing fluorescent dyes are limited in capacity of distinguishing bacteria from other microorganisms (such as fungi) and are prone to causing false positive. The stability is poor, and the specific storage requirement is generally required according to a product specification; meanwhile, the emission wavelength of the existing dye belongs to the range of green light or red light. Different from the existing fluorescent dye for staining bacteria, fungal staining is difficult to distinguish and the stability is poor, the invention discloses a specific living bacteria fluorescent dye which is extremely high in stability, the emission wavelength belongs to the blue light category, living cells and dead cells of gram-positive bacteria and gram-negative bacteria can be stained, and the specific living bacteria fluorescent dye has the advantages of high specificity and high specificity. However, RNA and DNA in eukaryotic cells cannot be dyed.
Owner:DIANDIAO (SUZHOU) LIFE TECHNOLOGY CO LTD
Method of screening for peptides capable of binding to a ubiquitin protein ligase (E3)
The present invention relates to a method of screening for peptides capable of binding to a ubiquitin protein ligase (E3), successful binding being determined by detecting the amount of a test protein in the cell. The invention relates to a method for determining if a peptide binds or is capable of binding to a ubiquitin protein ligase (E3) and thereby leads to degradation of a test protein, wherein the peptide is between about 7 and 110 amino acids in length, the method comprising: providing in a eukaryotic cell a candidate peptide functionally linked to a test protein, under conditions enabling ubiquitination of proteins by an E3; and detecting the amount of test protein present in the cell; whereby, a reduced amount of the test protein determines the candidate peptide as a peptide that binds or is capable of binding to an E3 (an E3-binding peptide).
Owner:PHOREMOST
Preparation method and application of recombinant human blood coagulation factor VII
The invention belongs to the technical field of medicine, and particularly relates to a preparation method and application of a recombinant human blood coagulation factor VII, and the preparation method comprises the following steps: transforming a nucleotide sequence of the recombinant human blood coagulation factor VII into a vector, and constructing a recombinant expression plasmid; transfecting the recombinant expression plasmid into a eukaryotic cell to obtain a recombinant expression cell; screening the recombinant expression cells to obtain stable transfected cells; domesticating the stably transfected cells to obtain monoclonal suspension engineered cells; and performing amplification culture on the monoclonal suspension engineered cells, collecting supernate, and extracting target protein in the supernate to obtain the recombinant human blood coagulation factor VII. The recombinant human blood coagulation factor VII produced by using the method disclosed by the invention is high in yield and good in procoagulant activity, so that the production efficiency and the application effect of the recombinant human blood coagulation factor VII can be improved by using the preparation method disclosed by the invention.
Owner:BEIJING TAIPU BIOTECHNOLOGY CO LTD
Novel trivalent DNA vaccine for coronavirus and preparation method thereof
The present application relates to the technical field of novel coronavirus, and particularly relates to a novel coronavirus trivalent DNA vaccine and a preparation method. The trivalent DNA vaccine takes a recombinant plasmid carrying a nucleotide sequence as shown in SEQ ID NO: 1 or 2 as an active ingredient. The trivalent DNA vaccine provided in the present application can express a fusion antigen protein of three kinds of antigen genes of the novel coronavirus in eukaryotic cells, and produce serum IgG antibodies against the three kinds of antigens of the novel coronavirus. In addition, the novel coronavirus trivalent DNA vaccine provided in the present application can immunize mice to produce T cells secreting various cytokines, and has a stronger T cell immune protection effect.
Owner:HUBEI UNIV OF MEDICINE
Chog cholera virus full-length infectious clone and construction method thereof
The invention relates to a hog cholera virus full-length infectious clone and a construction method thereof, the gene sequence of the hog cholera virus full-length infectious clone is as shown in SEQ ID NO.1, the used carrier is pBAC-smCSFV, through segmented PCR amplification and overlapping PCR connection, the genome sequence of a CSFV Shimen strain, a CMV promoter sequence, an RZ sequence and a BGH sequence are integrated into a bacterial artificial chromosome carrier, and the hog cholera virus full-length infectious clone is obtained. The complete hog cholera virus full-length infectious clone is obtained. According to the invention, a single-copy bacterial artificial chromosome vector and a human cytomegalovirus early promoter capable of starting RNA synthesis in eukaryotic cells are combined, and the construction method of the CSFV full-length infectious clone, which is simple and convenient to operate, efficient and stable, is provided. According to the method, the filial generation virus can be efficiently saved and obtained, and the filial generation virus rCSFV and the female parent wild type virus wtCSFV have the same growth characteristics and can be used for subsequent foundation and application research.
Owner:SOUTHWEST MEDICAL UNIV
Epigenetic reactivation of gamma-globin expression as a novel curative option for Β-hemoglobinopathies
Here, the inventors developed a strategy to modify the chromatin status of HSPCs at the HBG promoters to reactivate HbF expression. In particular, the inventors used from 1 to 4 single guide RNA (sgRNA) molecules spanning from the -220 to the -20 region of the HBG promoters together with CRISPR-based epigenome editors, namely dCas9-CBPcore and Tet1-dCas9. The first editor is capable of inserting histone acetylation while the second editor is performing DNA demethylation. Both epigenetic marks are associated with active transcription and are present in fetal erythroid cells expressing HbF. This strategy allows the ex vivo modification of adult HSCs to recreate a fetal-like epigenetic context leading to HbF production. Moreover, it avoids the genotoxicity associated with classical genome editing tools relying on DNA cleavage. Thus, the present invention relates to a method of increasing the expression of gamma globin in a population of eukaryotic cells through epigenome editing.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3
Systems and methods for utilizing plasma membrane-anchored proteases
This article describes a system comprising eukaryotic cells, wherein the eukaryotic cells include: a plasma membrane polypeptide coupled to a transcription factor via a linker, wherein the linker contains a protease-cleavable site; and a plasma membrane-anchored protease, wherein the plasma membrane-anchored protease is capable of cleaving the linker. The system may further include a reporter construct, wherein the transcription factor can bind to the promoter of the reporter construct to indicate the ability of the plasma membrane polypeptide to be transported to the plasma membrane.
Owner:OCTANT INC
Specific primer of DHRS4 gene, detection kit, overexpression vector and application thereof
PendingCN121700066APeptide/protein ingredientsDigestive systemEucaryotic cellTreatment of lung cancer
The invention relates to a DHRS4 gene specific primer, a detection kit, an overexpression vector and application thereof, and belongs to the technical field of biological medicine. In order to overcome the defects in the prior art, the invention provides a specific primer, a detection kit and an overexpression vector of the DHRS4 gene, and the specific primer, the detection kit and the overexpression vector have remarkable beneficial effects and wide application prospects in the field of diagnosis and treatment of lung cancer and colorectal cancer. Researches prove that the expression level of the DHRS4 gene in tumor tissues of lung cancer patients and colorectal cancer patients is remarkably reduced, the expression condition of the DHRS4 gene can be rapidly detected by specific primers, and a reliable basis is provided for auxiliary diagnosis of lung cancer or colorectal cancer. The DHRS4 gene overexpression vector can effectively express DHRS4 protein in eukaryotic cells, proliferation, clone formation and migration of lung cancer and colorectal cancer cells are inhibited by restoring or enhancing expression of the DHRS4 gene, and a brand new strategy is provided for targeted therapy of lung cancer and colorectal cancer.
Owner:HARBIN MEDICAL UNIVERSITY
A dual domain recombinant humanized fibronectin and preparation and application thereof
The application discloses a double-domain recombinant humanized fibronectin, the sequence of which is shown as SEQ ID NO. 3, which is composed of the collagen binding domain and the cell binding domain of human fibronectin. The application also provides a recombinant expression vector and a host cell containing the gene coding the protein. The protein is efficiently expressed by eukaryotic cells and engineered Escherichia coli, and a fermentation and purification process suitable for industrial scale is established. Functional experiments prove that, compared with the single-domain commercial fibronectin product, the double-domain recombinant humanized fibronectin of the application can significantly promote the proliferation, migration, adhesion and differentiation activity of human skin fibroblasts, and has wide application potential in the fields of skin repair, beauty and skin care and biomedical materials.
Owner:BAYI MEIHENG (BEIJING) TECH CO LTD
Engineered modular recombinase compositions, methods, and systems for site-specific DNA recombination
PCT designated stageWO2025212976A3TransferasesStable introduction of DNAEucaryotic cellSite-specific recombination
Disclosed are altered recombinases wherein at least one amino acid is different from a parent, wildtype recombinase and the altered recombinase has improved recombination efficiency towards wild-type and / or pseudo att site sequences relative to the parent, wildtype recombinase. Disclosed are altered modular recombinases comprising binding (or interacting) regions from a different recombinase. Disclosed are methods of modifying the genomes of cells using the altered recombinases, including methods of site-specifically integrating a polynucleotide sequence of interest in a genome of a eucaryotic cell.
Owner:SANGAMO THERAPEUTICS INC
A fusion protein and immunogenic composition for preventing toxoplasma infection and application thereof
PendingCN122127483AProtozoa antigen ingredientsAntiparasitic agentsEucaryotic cellRecombinant vaccines
This invention relates to fusion proteins, immunogenic compositions, recombinant vaccines, and applications for the prevention of Toxoplasma gondii infection. From a reverse vaccinology perspective, this invention, through screening and optimization, provides a novel fusion molecular structure comprising a fusion protein encoded by two genes: the SPATR antigen and the MIC2 antigen. This fusion protein can be successfully translated, correctly folded, and secreted extracellularly in eukaryotic cells. Based on the aforementioned SPATR-MIC2 fusion mRNA vaccine, a 100% protective effect against Toxoplasma gondii infection can be achieved in a mouse model of Toxoplasma gondii infection, significantly superior to the inactivated vaccine group. The fusion protein of this invention exhibits good immunogenicity and can provide effective immune protection against Toxoplasma gondii infection, showing broad application prospects.
Owner:NANJING CHENGSHI BIOMEDICAL TECH CO LTD
An anti-enzymatic antibacterial peptide FRL and its preparation method and application
The present invention discloses an anti - enzymolysis antibacterial peptide FRL, its preparation method and application, belonging to the field of bioengineering. The sequence of the antibacterial peptide FRL is shown as SEQ ID No.1. This antibacterial peptide FRL exhibits narrow - spectrum antibacterial activity, can effectively inhibit Gram - negative bacteria, and has the potential to be applied in drugs for treating Gram - negative bacterial infectious diseases. This antibacterial peptide has very low hemolytic activity and eukaryotic cell toxicity. This antibacterial peptide fails to cause 10% erythrocyte hemolysis at a concentration of 128 μmol / L, and the survival rate of mouse macrophage RAW264.7 reaches more than 80%. This antibacterial peptide shows good stability against trypsin, pepsin, chymotrypsin, and proteinase K (0.4 mg / mL; 0.5 h) at pH = 5 and 37°C. In summary, the antibacterial peptide FRL has the development potential to become an alternative to antibiotics.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY
Anti-helicobacter pylori monoclonal antibody as well as preparation and application thereof
The invention discloses an anti-helicobacter pylori monoclonal antibody as well as preparation and application thereof, and belongs to the technical field of medical detection. The antibody is prepared by taking inactivated helicobacter pylori ATCC 43504 whole bacteria as an immunogen, immunizing a New Zealand white rabbit and then carrying out single B cell sorting, limited dilution, gene cloning, plasmid construction and eukaryotic cell expression, has a specific CDR core sequence, is high in specificity and affinity, can accurately recognize a helicobacter pylori specific antigen, and can be used for preparing a specific antibody. The cross reaction with other bacteria or tissue impurities is effectively avoided. The kit can be used for detecting the helicobacter pylori, and a new tool and method are provided for pathological diagnosis of helicobacter pylori infection and related digestive system diseases.
Owner:NANJING UNIONWAY BIOTECHNOLOGY CO LTD +1
Duck enteritis virus gC protein polyclonal antibody, preparation method thereof and duck enteritis virus detection reagent
The invention discloses a duck enteritis virus gC protein polyclonal antibody, a preparation method thereof and a duck enteritis virus detection reagent. The preparation method comprises the following steps: connecting an optimized gC protein coding gene as shown in SEQ ID No: 4 to a prokaryotic expression vector, and constructing to obtain a recombinant plasmid; after the recombinant plasmids are transformed into competent cells, the purified recombinant gC protein is obtained through induced expression and purification; the recombinant gC protein is used as an immunogen to immunize a donor animal to obtain the duck enteritis virus gC protein polyclonal antibody. According to the invention, codon optimization, cloning and prokaryotic expression are carried out on the basis of the specific UL44 gene for coding the gC protein, so that the anti-DEV gC protein murine and rabbit polyclonal antibody is successfully prepared. The preparation method of the polyclonal antibody is simple and low in cost, and the obtained antibody is high in titer and can specifically recognize the duck enteritis virus gC protein in eukaryotic cells.
Owner:JIANGSU AGRI ANIMAL HUSBANDRY VOCATIONAL COLLEGE
Molecular therapeutic strategy combining idelalisib and srpin340 to treat advance solid tumors
PI3Kδ implicates hematologic cancers and solid tumors. Alternative splicing is a post-transcriptional process for acquiring proteomic diversity in eukaryotic cells. Emerging evidence highlights the involvement of aberrant mRNA splicing in cancer development / progression. PI3Kδ-L and PI3Kδ-S are overexpressed in advanced solid tumors, such as prostate, breast, colon, lung and pancreatic cancers. Differential PI3Kδ and PI3Kδ-S expression profiles were identified in a panel of solid tumor cells. PI3Kδ inhibitor Idelalisib and SRPK1 / 2 inhibitor SRPIN340 were employed to assess their efficacies on inhibiting the PI3Kδ-expressing solid tumors. Idelalisib effectively inhibits PI3Kδ-L and its downstream signaling. Idelalisib fails to inhibit PI3Kδ-S activity and its downstream signaling. SRPIN340 reverses the aberrant mRNA splicing, thereby inhibiting the downstream AKT / mTOR signaling. In vitro functional assays further demonstrate that a combination of Idelalisib and SRPIN340 achieve a synergistic drug effect, with drastically reduced cell viabilities / growths of tumor spheroids, in inhibiting the advanced tumor cells.
Owner:UNIV OF MARYLAND EASTERN SHORE
Method for producing N-acetylneuraminic acid
The present invention relates to a method for producing N-acetylneuraminic acid, comprising the steps of: infecting eukaryotic cells with a baculovirus bearing an exogenous gene encoding an N-acetylglucosamine 2-epimerase and an N-acetylneuraminic acid aldolase, the N-acetylglucosamine 2-epimerase and the N-acetylneuraminic acid aldolase can be expressed by the aid of the N-acetylglucosamine 2-epimerase; and culturing the obtained eukaryotic cell infected by the baculovirus in the presence of N-acetyl glucosamine and pyruvic acid.
Owner:CPC CORPORATION
A uorf element for regulating expression of chicken insulin receptor and application thereof
ActiveCN120796258BEucaryotic cellLow insulin
The application discloses a uORF element for regulating chicken insulin receptor expression and application thereof, belongs to the field of molecular biology and genetic engineering, and the nucleotide sequence of the uORF element is shown in any one of SEQ ID NO. 1-2; the application comprises any one of the following: (1) regulating the expression of firefly luciferase in eukaryotic cells; the eukaryotic cells are chicken embryo fibroblasts and chicken preadipocytes; (2) being applied to genetic breeding of chickens, and the genetic breeding is breeding of meat chickens with reduced insulin resistance; (3) application in preparation of a reagent for regulating the expression of chicken insulin receptors. The application can regulate the expression level of INSR, improve insulin sensitivity, and provide material support for research on the mechanism of insulin in regulating blood glucose.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY
An electrotransfection method for eukaryotic cells
ActiveCN115927465BElectrical/wave energy microorganism treatmentVector-based foreign material introductionEucaryotic cellThreonine
The present invention relates to an electrotransfection method for eukaryotic cells. The transfection method comprises the following steps: (1) mixing a first buffer solution with a nucleic acid fragment or a plasmid containing a nucleic acid fragment to obtain a transfection gene solution; (2) mixing the cells to be transfected with a second buffer solution, standing for equilibration, centrifuging to obtain a precipitate and mixing it with the transfection gene solution, standing for incubation, and resuspending; (3) performing pulsed electric shock on the resuspended solution at 100-300 V, 80-300 μs, for 1-3 times, standing for incubation. The pH values of the first buffer solution and the second buffer solution are 7.2±0.2 respectively, the osmotic pressure of the first buffer solution is 230-280 mOsmol / kg, the osmotic pressure of the second buffer solution is 280-320 mOsmol / kg, the osmotic pressure of the first buffer solution is smaller than that of the second buffer solution, and they respectively contain glucose, threonine and / or asparagine. The present invention can better balance the cell transfection efficiency and cell survival rate.
Owner:SUZHOU EXCELL BIOLOGICAL TECH CO LTD
Application of Hacl1 gene in the preparation of drugs for treating RNA virus infection-related diseases and maintaining innate immune homeostasis
The present invention discloses the use of the Hacl1 gene in the preparation of drugs for treating RNA virus infection-related diseases and maintaining innate immune homeostasis, and relates to the field of biomedicine technology. The present invention finds that the transcription level of Hacl1 is significantly upregulated during the infection of eukaryotic cells by RNA viruses represented by NDV and VSV. After knocking down Hacl1 using siRNA, viral proliferation was significantly inhibited, while overexpression of HACL1 had a significant promoting effect on the proliferation of NDV virus in eukaryotic cells. Further testing found that knocking down Hacl1 could increase the transcription levels of IFNβ, ISG15, IFIT2 and MX1 in cells, thereby inhibiting the replication of the virus in cells. The above suggests that the HACL1 protein plays an important role in RNA virus-related infectious diseases and innate immune regulation, providing a new basis for the clinical participation of HACL1 in regulating innate immune responses, and has broad application prospects in the field of RNA virus vaccine development.
Owner:ANHUI UNIV
Electro-transfection device for eukaryotic cells
ActiveCN223674654UBioreactor/fermenter combinationsBiological substance pretreatmentsEucaryotic cellScrew thread
Owner:THE THIRD MEDICAL CENT OF THE CHINESE PEOPLES LIBERATION ARMY GENERAL HOSPITAL